This content is machine translated Mental Health with GLP-1 RAs Benefits of Semaglutide and Liraglutide GLP-1 receptor agonists are established treatments for type 2 diabetes and obesity. Depression and anxiety disorders are common among people with diabetes and obesity, and both conditions are associated with...…
View Post 7 min This content is machine translated Obesity in Children and Adolescents Gene-Environment Interactions: Polygenic or Monogenic Determinants? In the context of precision medicine, a differentiated approach to the diagnosis of obesity provides an essential foundation for implementing improved strategies for prevention, treatment, and prognosis. Obesity is often...…
View Post 7 min This content is machine translated Obesity: A Multimodal and Interdisciplinary Approach New Swiss Clinical Practice Guideline Provides Guidance The guidelines developed by Swiss professional associations (Swiss Obesity Clinical Practice Guidance) contain evidence-based recommendations for the diagnosis and treatment of obesity, with a focus on improving health, quality of...…
View Post 6 min This content is machine translated Incretin mimetics for obesity and prediabetes Liraglutide, semaglutide and tirzepatide: considerable evidence base Weight reduction is an important therapeutic measure in diabetes prevention. Prediabetes is characterized by elevated fasting blood sugar and/or impaired glucose tolerance, but not yet manifest diabetes. In obese people,...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 10 min This content is machine translated Mechanisms, evidence and therapeutic consequences GLP-1 receptor agonists in cardiology GLP-1 receptor agonists (GLP-1RAs) have rapidly evolved from antidiabetic drugs to cardiometabolic therapies with clinically proven reductions in hard cardiovascular endpoints – and increasingly beyond the traditional diabetes population. The...…
View Post 6 min This content is machine translated Obesity therapy Why lifestyle modification alone is not effective According to current understanding, obesity is considered a multifactorial chronic disease. The overriding goals of treatment are to improve the general state of health and weight-associated diseases or risk factors.…
View Post 5 min This content is machine translated Obesity The pounds tumble under incretin-based therapies Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the…
View Post 5 min This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
View Post 6 min This content is machine translated Incretin-based therapies for type 2 diabetes Evolution of therapy options continues Incretin mimetics are an attractive treatment option, particularly for the subgroup of overweight type 2 diabetics, as they not only have glucose-lowering effects, but have also demonstrated clinical benefits in…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…
